Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands; Netherlands Heart Institute, Utrecht, the Netherlands.
Netherlands Heart Institute, Utrecht, the Netherlands; Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
JACC Cardiovasc Imaging. 2021 May;14(5):885-896. doi: 10.1016/j.jcmg.2020.09.030. Epub 2020 Nov 18.
This study aimed to explore echocardiographic characteristics of phospholamban (PLN) p.Arg14del mutation carriers to investigate whether structural and/or functional abnormalities could be identified before onset of symptoms.
Carriers of the genetic PLN p.Arg14del mutation may develop arrhythmogenic and/or dilated cardiomyopathy. Overt disease is preceded by a pre-symptomatic phase of variable length in which disease expression seems to be absent.
PLN p.Arg14del mutation carriers with an available echocardiogram were included. Mutation carriers were classified as pre-symptomatic if they had no history of ventricular arrhythmias (VAs), a premature ventricular complex count of <500/24 h, and a left ventricular (LV) ejection fraction of ≥45%. In addition, we included 70 control subjects with similar age and sex distribution as the pre-symptomatic mutation carriers. Comprehensive echocardiographic analysis (including deformation imaging) was performed.
The final study population consisted of 281 PLN p.Arg14del mutation carriers, 139 of whom were classified as pre-symptomatic. In comparison to control subjects, pre-symptomatic mutation carriers had lower global longitudinal strain and higher LV mechanical dispersion (both p < 0.001). In addition, post-systolic shortening (PSS) in the LV apex was observed in 43 pre-symptomatic mutation carriers (31%) and in none of the control subjects. During a median follow-up of 3.2 years (interquartile range: 2.1 to 5.6 years) in 104 pre-symptomatic mutation carriers, nonsustained VA occurred in 13 (13%). Presence of apical PSS was the strongest echocardiographic predictor of VA (multivariable hazards ratio: 5.11; 95% confidence interval [CI]: 1.37 to 19.08; p = 0.015), which resulted in a negative predictive value of 96% (95% CI: 89% to 98%) and a positive predictive value of 29% (95% CI: 21% to 40%).
Global and regional LV mechanical alterations in PLN p.Arg14del mutation carriers precede arrhythmic symptoms and overt structural disease. Pre-symptomatic mutation carriers with normal deformation patterns in the apex are at low risk of developing VA within 3 years, whereas mutation carriers with apical PSS appear to be at higher risk.
本研究旨在探讨磷酸化酶结合蛋白(PLN)p.Arg14del 突变携带者的超声心动图特征,以探究在症状出现前是否能识别到结构和/或功能异常。
携带 PLN 基因 p.Arg14del 突变的携带者可能会发展为致心律失常性和/或扩张型心肌病。显性疾病之前存在一个长短不一的无症状前阶段,在此期间似乎没有疾病表现。
纳入携带 PLN p.Arg14del 突变且有超声心动图检查结果的患者。如果患者无室性心律失常(VA)病史、室性早搏计数<500/24 h 且左心室(LV)射血分数≥45%,则将其归类为无症状前阶段。此外,我们还纳入了 70 名年龄和性别分布与无症状前阶段突变携带者相似的对照组。对所有患者进行全面的超声心动图分析(包括应变成像)。
最终的研究人群包括 281 名 PLN p.Arg14del 突变携带者,其中 139 名被归类为无症状前阶段。与对照组相比,无症状前阶段突变携带者的整体纵向应变较低,LV 机械弥散度较高(均 P<0.001)。此外,43 名无症状前阶段突变携带者(31%)的 LV 心尖段出现收缩后缩短(PSS),而对照组无一例出现。在 104 名无症状前阶段突变携带者的中位随访 3.2 年(四分位距:2.1 至 5.6 年)期间,13 名(13%)患者发生非持续性 VA。LV 心尖段存在 PSS 是 VA 的最强超声心动图预测因素(多变量风险比:5.11;95%置信区间[CI]:1.37 至 19.08;P=0.015),其阴性预测值为 96%(95%CI:89%至 98%),阳性预测值为 29%(95%CI:21%至 40%)。
PLN p.Arg14del 突变携带者的整体和局部 LV 机械改变先于心律失常症状和明显的结构性疾病。在 3 年内,具有正常心尖段应变模式的无症状前阶段突变携带者发生 VA 的风险较低,而具有心尖段 PSS 的突变携带者发生 VA 的风险较高。